- Home
- APLM vs CYCN Comparison
APLM vs CYCN Comparison
Compare APLM & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- CYCN
- Stock Information
- Founded
- APLM 2016
- CYCN 2018
- Country
- APLM United States
- CYCN United States
- Employees
- APLM N/A
- CYCN N/A
- Industry
- APLM Blank Checks
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- CYCN Health Care
- Exchange
- APLM Nasdaq
- CYCN Nasdaq
- Market Cap
- APLM 7.7M
- CYCN 7.5M
- IPO Year
- APLM N/A
- CYCN N/A
- Fundamental
- Price
- APLM $6.71
- CYCN $2.58
- Analyst Decision
- APLM Strong Buy
- CYCN
- Analyst Count
- APLM 2
- CYCN 0
- Target Price
- APLM $425.00
- CYCN N/A
- AVG Volume (30 Days)
- APLM 42.6K
- CYCN 26.5K
- Earning Date
- APLM 04-15-2025
- CYCN 03-04-2025
- Dividend Yield
- APLM N/A
- CYCN N/A
- EPS Growth
- APLM N/A
- CYCN N/A
- EPS
- APLM N/A
- CYCN N/A
- Revenue
- APLM $2,101,000.00
- CYCN $2,000,000.00
- Revenue This Year
- APLM N/A
- CYCN N/A
- Revenue Next Year
- APLM N/A
- CYCN N/A
- P/E Ratio
- APLM N/A
- CYCN N/A
- Revenue Growth
- APLM 70.54
- CYCN N/A
- 52 Week Low
- APLM $6.20
- CYCN $1.27
- 52 Week High
- APLM $63.00
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- APLM 43.33
- CYCN 46.16
- Support Level
- APLM $6.20
- CYCN $2.44
- Resistance Level
- APLM $8.00
- CYCN $2.68
- Average True Range (ATR)
- APLM 1.37
- CYCN 0.20
- MACD
- APLM -0.18
- CYCN 0.02
- Stochastic Oscillator
- APLM 9.44
- CYCN 29.46
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.